Therapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection
Pathogens · 2025
DOI: 10.3390/pathogens14101038 ↗At a glance
Journal article in Pathogens, 2025. Written by Yiting Zhang and 7 co-authors. Institution: Anhui Provincial Key Laboratory of Zoonoses, Department of Microbiology and Parasitology, School of Basic Medical Sciences, Anhui Medical University,…. Major MEDLINE topics: Pneumonia, Mycoplasma, Mycoplasma pneumoniae, Antibodies, Bacterial, Antigens, Bacterial. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: Scientific Research Project of Higher Education Institutions in Anhui Province, the Scientific Research Fund of Anhui Institute of Translational Medicine, Anhui Medical University 2024 Clinical Medicine ("5+3" integration) Major (Grade2023) "Early Contact Research" training Program (2024-ZQKY-174).
Abstract (original language)
The aim of this study was to investigate the therapeutic potential of a polyclonal antibody against the Mycoplasma pneumoniae (MP) P116-661 protein. A polyclonal antibody against the P116-661 protein was obtained by immunizing New Zealand white rabbits, and its therapeutic effects were systematically evaluated by various experimental methods. An immunofluorescence assay was used to detect the inhibitory effect of the P116-661 polyclonal antibody on the adhesion of MP cells to A549 cells. ELISAs and Western blotting were used to analyze the expression levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and model mice after MP infection. HE staining was used to observe pathological changes in the lung tissue of the infected mice. The results showed that the P116-661 polyclonal antibody effectively inhibited the adhesion of MP cells to A549 cells. It significantly reduced the secretion levels of inflammatory factors, such as IL-6 and TNF-α, in Beas-2b cells and mice after MP infection. Moreover, the antibody significantly improved the pathological damage to the lungs that was caused by MP infection in mice. This study confirms that the P116-661 polyclonal antibody has good therapeutic effects in vitro and in vivo, providing a new experimental basis for immunotherapy against MP infection.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Anhui Provincial Key Laboratory of Zoonoses, Department of Microbiology and Parasitology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
- Department of The Second Clinical School of Medicine, Anhui Medical University, Hefei 230032, China.
- Department of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
Funding
- Scientific Research Project of Higher Education Institutions in Anhui Province
- the Scientific Research Fund of Anhui Institute of Translational Medicine
- Anhui Medical University 2024 Clinical Medicine ("5+3" integration) Major (Grade2023) "Early Contact Research" training Program (2024-ZQKY-174)
- Anhui Medical University 2023 Clinical Medicine ("5+3" integration) Major (Grade2022)
- "Early Contact Research" training Program (2023-ZQKY-156).
Cite
APA
Zhang, Y., Geng, X., Liu, Y., Li, W., Shao, F., Jin, M., Wang, J., & Wang, L. (2025). Therapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection. Pathogens. https://doi.org/10.3390/pathogens14101038
Vancouver
Zhang Y, Geng X, Liu Y, Li W, Shao F, Jin M, et al. Therapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection. Pathogens. 2025. doi:10.3390/pathogens14101038
BibTeX
@article{Zhang2025,
author = {Zhang, Yiting and Geng, Xinqi and Liu, Yan and Li, Wenli and Shao, Feng and Jin, Mengmeng and Wang, Jinzhi and Wang, Linding},
title = {Therapeutic Efficacy of an Anti-P116-661 Polyclonal Antibody Against Mycoplasma pneumoniae Infection},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14101038}
}
EUVIMED